Real-time Estimate
Cboe BZX
08:48:35 29/04/2024 pm IST
|
5-day change
|
1st Jan Change
|
340.3
USD
|
+1.40%
|
|
+3.74%
|
+13.51%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
78,602
|
92,084
|
1,00,882
|
92,522
|
1,13,776
|
1,27,620
|
-
|
-
|
Enterprise Value (EV)
1 |
84,408
|
1,02,290
|
1,10,335
|
1,02,451
|
1,21,655
|
1,35,375
|
1,32,973
|
1,30,360
|
P/E ratio
|
38.3
x
|
58.3
x
|
51.3
x
|
39.6
x
|
36.3
x
|
33.6
x
|
29.4
x
|
26.2
x
|
Yield
|
1.02%
|
0.96%
|
0.97%
|
1.16%
|
-
|
0.95%
|
1.03%
|
1.09%
|
Capitalization / Revenue
|
5.28
x
|
6.42
x
|
5.9
x
|
5.02
x
|
5.55
x
|
5.76
x
|
5.35
x
|
4.98
x
|
EV / Revenue
|
5.67
x
|
7.13
x
|
6.45
x
|
5.55
x
|
5.93
x
|
6.11
x
|
5.58
x
|
5.09
x
|
EV / EBITDA
|
20
x
|
26.6
x
|
23.2
x
|
21.5
x
|
22.7
x
|
22.7
x
|
20
x
|
18.1
x
|
EV / FCF
|
54.7
x
|
36.7
x
|
40.3
x
|
50.3
x
|
39.2
x
|
38.8
x
|
32.3
x
|
28.8
x
|
FCF Yield
|
1.83%
|
2.73%
|
2.48%
|
1.99%
|
2.55%
|
2.58%
|
3.09%
|
3.48%
|
Price to Book
|
6.14
x
|
7.04
x
|
6.79
x
|
5.56
x
|
6.11
x
|
6.03
x
|
5.36
x
|
4.73
x
|
Nbr of stocks (in thousands)
|
3,74,400
|
3,75,791
|
3,77,240
|
3,78,430
|
3,79,938
|
3,80,264
|
-
|
-
|
Reference price
2 |
209.9
|
245.0
|
267.4
|
244.5
|
299.5
|
335.6
|
335.6
|
335.6
|
Announcement Date
|
28/01/20
|
27/01/21
|
27/01/22
|
31/01/23
|
30/01/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
14,884
|
14,351
|
17,108
|
18,449
|
20,498
|
22,174
|
23,835
|
25,608
|
EBITDA
1 |
4,222
|
3,839
|
4,753
|
4,755
|
5,348
|
5,972
|
6,641
|
7,201
|
EBIT
1 |
3,908
|
3,499
|
4,382
|
4,384
|
4,955
|
5,574
|
6,210
|
6,788
|
Operating Margin
|
26.26%
|
24.38%
|
25.61%
|
23.76%
|
24.17%
|
25.14%
|
26.05%
|
26.51%
|
Earnings before Tax (EBT)
1 |
2,562
|
1,954
|
2,281
|
2,683
|
3,673
|
4,561
|
5,202
|
5,876
|
Net income
1 |
2,083
|
1,599
|
1,994
|
2,358
|
3,165
|
3,877
|
4,396
|
4,913
|
Net margin
|
13.99%
|
11.14%
|
11.66%
|
12.78%
|
15.44%
|
17.49%
|
18.44%
|
19.18%
|
EPS
2 |
5.480
|
4.200
|
5.210
|
6.170
|
8.250
|
9.989
|
11.41
|
12.79
|
Free Cash Flow
1 |
1,542
|
2,790
|
2,738
|
2,036
|
3,105
|
3,490
|
4,111
|
4,533
|
FCF margin
|
10.36%
|
19.44%
|
16%
|
11.04%
|
15.15%
|
15.74%
|
17.25%
|
17.7%
|
FCF Conversion (EBITDA)
|
36.52%
|
72.68%
|
57.61%
|
42.82%
|
58.06%
|
58.44%
|
61.89%
|
62.95%
|
FCF Conversion (Net income)
|
74.03%
|
174.48%
|
137.31%
|
86.34%
|
98.1%
|
90.01%
|
93.51%
|
92.28%
|
Dividend per Share
2 |
2.135
|
2.355
|
2.585
|
2.835
|
-
|
3.189
|
3.446
|
3.643
|
Announcement Date
|
28/01/20
|
27/01/21
|
27/01/22
|
31/01/23
|
30/01/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
4,160
|
4,701
|
4,275
|
4,493
|
4,479
|
5,202
|
4,778
|
4,996
|
4,909
|
5,815
|
5,105
|
5,392
|
5,345
|
6,333
|
5,484
|
EBITDA
1 |
1,149
|
1,378
|
1,026
|
1,156
|
1,092
|
1,481
|
1,102
|
1,314
|
1,247
|
1,685
|
1,223
|
1,453
|
1,430
|
1,902
|
1,383
|
EBIT
1 |
1,058
|
1,285
|
934
|
1,063
|
1,001
|
1,386
|
1,006
|
1,216
|
1,149
|
1,584
|
1,121
|
1,345
|
1,322
|
1,799
|
1,281
|
Operating Margin
|
25.43%
|
27.33%
|
21.85%
|
23.66%
|
22.35%
|
26.64%
|
21.05%
|
24.34%
|
23.41%
|
27.24%
|
21.96%
|
24.94%
|
24.74%
|
28.4%
|
23.35%
|
Earnings before Tax (EBT)
1 |
495
|
757
|
386
|
720
|
816
|
761
|
679
|
899
|
869
|
1,226
|
892.7
|
1,108
|
1,074
|
1,626
|
1,034
|
Net income
1 |
438
|
662
|
323
|
656
|
816
|
563
|
592
|
738
|
692
|
1,143
|
761.1
|
943.3
|
935.9
|
1,352
|
942.5
|
Net margin
|
10.53%
|
14.08%
|
7.56%
|
14.6%
|
18.22%
|
10.82%
|
12.39%
|
14.77%
|
14.1%
|
19.66%
|
14.91%
|
17.5%
|
17.51%
|
21.34%
|
17.19%
|
EPS
2 |
1.140
|
1.730
|
0.8400
|
1.720
|
2.140
|
1.470
|
1.540
|
1.930
|
1.800
|
2.980
|
1.931
|
2.424
|
2.394
|
3.464
|
2.450
|
Dividend per Share
2 |
0.6300
|
0.6950
|
0.6950
|
0.6950
|
0.6950
|
0.7500
|
0.7500
|
0.7500
|
0.7500
|
-
|
0.7908
|
0.7933
|
0.7901
|
0.7926
|
0.8449
|
Announcement Date
|
28/10/21
|
27/01/22
|
28/04/22
|
26/07/22
|
31/10/22
|
31/01/23
|
01/05/23
|
03/08/23
|
02/11/23
|
30/01/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
5,806
|
10,206
|
9,453
|
9,929
|
7,879
|
7,755
|
5,353
|
2,740
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.375
x
|
2.659
x
|
1.989
x
|
2.088
x
|
1.473
x
|
1.299
x
|
0.806
x
|
0.3805
x
|
Free Cash Flow
1 |
1,542
|
2,790
|
2,738
|
2,036
|
3,105
|
3,490
|
4,111
|
4,533
|
ROE (net income / shareholders' equity)
|
25.6%
|
21.8%
|
24.8%
|
22.7%
|
23.1%
|
22.8%
|
22.1%
|
21.2%
|
ROA (Net income/ Total Assets)
|
10.9%
|
8.77%
|
10.1%
|
9.99%
|
10.6%
|
10.7%
|
11.7%
|
12.3%
|
Assets
1 |
19,044
|
18,240
|
19,791
|
23,611
|
29,877
|
36,224
|
37,464
|
39,914
|
Book Value Per Share
2 |
34.20
|
34.80
|
39.40
|
43.90
|
49.00
|
55.60
|
62.70
|
70.90
|
Cash Flow per Share
2 |
5.770
|
8.620
|
8.540
|
6.870
|
9.590
|
11.80
|
13.30
|
14.50
|
Capex
1 |
649
|
487
|
525
|
588
|
575
|
669
|
707
|
758
|
Capex / Sales
|
4.36%
|
3.39%
|
3.07%
|
3.19%
|
2.81%
|
3.02%
|
2.96%
|
2.96%
|
Announcement Date
|
28/01/20
|
27/01/21
|
27/01/22
|
31/01/23
|
30/01/24
|
-
|
-
|
-
|
Last Close Price
335.6
USD Average target price
365.7
USD Spread / Average Target +8.96% Consensus |
1st Jan change
|
Capi.
|
---|
| +13.51% | 128B | | -8.61% | 10.65B | | +0.91% | 8.82B | | +19.36% | 7.19B | | +21.70% | 4.99B | | +7.31% | 3.4B | | -0.32% | 3.03B | | -8.73% | 2.14B | | -10.15% | 2B | | -22.81% | 1.79B |
Medical Devices & Implants
|